Related Experiment Video
Updated: Aug 6, 2025

Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines
Published on: November 25, 2017
Better Peptides via Chemical Glycosylation: Somatostatin Analogues Having a Human Complex-Type N-Glycan with Improved
Hirofumi Ochiai1, Taiji Shimoda1, Kazuhiro Fukae1,2
1GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.
Abstract:
Somatostatin (somatotropin release-inhibiting factor, SRIF) is a growth hormone inhibitory factor in the form of a 14- or 28-amino acid peptide. SRIF affects several physiological functions through its action on five distinct SRIF receptor subtypes (sst1-5). Native SRIF has only limited clinical applications due to its rapid degradation in plasma. To overcome this obstacle, we have developed glycosylated SRIF analogues that possess not only metabolic stability but also high affinity to all five receptor subtypes by attaching human complex-type oligosaccharides. Such glycosylated SRIF analogues with improved pharmacokinetic profiles could be potent and novel therapeutic drugs for SRIF-related diseases in which several SRIF receptor subtypes are closely involved, and also shed light on new indications. Our results show that chemical glycosylation can be a powerful tool for the development of peptide and protein analogues superior to the original molecules with enhanced drug properties.
Related Concept Videos
Protein Glycosylation
Glycosylation occurs in...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Proteoglycans
Drug Metabolism: Phase II Reactions
Oral Hypoglycemic Agents: Glinides

